WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced a significant milestone in its strategic collaboration with Earendil Labs, as an innovative trispecific antibody for ophthalmic diseases developed under the partnership marked WuXi Biologics’ 1,000th molecule on its integrated CRDMO platform.

Through the collaboration, the two companies have worked closely to advance Earendil Labs’ multiple novel bispecific and multispecific antibodies, fusion proteins, and ADCs from DNA to IND with timelines outperforming industry averages. By combining Earendil Labs’ innovation capabilities with WuXi Biologics’ integrated CRDMO platform, the collaboration has demonstrated how scientific innovation and CRDMO execution can work together to de-risk development, compress timelines, and support the progression of multiple programs across autoimmune diseases, oncology, and other serious conditions.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “Reaching the 1,000th molecule milestone is a significant moment in our journey of enabling global innovation. It reflects the confidence that our global partners place in WuXi Biologics’ integrated CRDMO platform, a robust quality system and consistent execution. More importantly, it reminds us to stay true to why we started — to be a trusted partner to our clients, honor every commitment with reliable execution, and translate innovation into high-quality biologics. Guided by our vision that every biologic can be made, we remain committed to enabling our partners to accelerate the discovery, development and manufacturing of life-changing therapies to patients worldwide.”

Dr. Jian Peng, CEO of Earendil Labs, commented, “WuXi Biologics has proven to be a trusted partner with deep insight into the unique challenges of complex biologics and the capability to solve them with speed, rigor, and reliability. As Earendil Labs continues to leverage AI to transform protein therapeutics discovery and advance a new generation of innovative medicines, this collaboration gives us a strong foundation to translate our scientific vision into high-quality therapeutic candidates. We look forward to accelerating more programs toward the clinic and, ultimately, bringing meaningful new treatment options to patients.”

Dr. Zhenping Zhu, President & Co-CEO of Earendil Labs, commented, “The achievement of WuXi Biologics’ 1,000th molecule milestone within the context of our collaboration underscores our strength of integrated innovative discovery with its highly efficient development and manufacturing platform. Working with WuXi Biologics, we have been able to rapidly advance a diverse portfolio with enhanced speed and quality. We look forward to further deepening this collaboration to bring forward next-generation biologics for patients worldwide.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the “2026 Biologics CDMO of the Year” (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the “2026 Best Contract Development & Manufacturing Organization Award” (ABEA)

About Earendil Labs 

Earendil Labs is an AI-powered biotechnology company advancing next-generation biologics for patients with autoimmune diseases, cancer, and other areas of significant unmet medical need. By integrating artificial intelligence across the full R&D lifecycle, Earendil Labs and its affiliate Helixon Therapeutics are building a scalable engine to systematically generate and advance high-quality therapeutic programs.

The company’s AI-native approach enables efficient creation, optimization, and progression of protein-based biologics with the potential to be first-in-class and best-in-class, translating computational innovation into real clinical and patient impact. Through a combination of internal pipeline development and strategic partnerships, Earendil Labs aims to deliver transformative medicines to patients worldwide.

For more information about Earendil Labs, please visit: www.earendil.bio.

WuXi Biologics Contacts
Business
info@wuxibiologics.com

Media
PR@wuxibiologics.com

 

Source: wuxibiologics.com

Report Abuse